Aurobindo Pharma is looking forward to setting up a new drug formulation plant in Hyderabad, Andhra Pradesh.
The proposed plant will manufacture some of Actavis' products domestically. It is expected to be commissioned by 2016. The transfer of licences is expected to be completed in six months. Aurobindo Pharma requires a minimum investment of Rs 100 crore to set up the project.
In January 2014, Aurobindo Pharma received the final approval from the US Food & Drug Administration to manufacture and market Repaglinide Tablets USP 0.5 mg, 1 mg and 2 mg. The product is ready for launch.